Pipendoxifene

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Pipendoxifene
Pipendoxifene skeletal.svg
Clinical data
Synonyms ERA-923
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Molar mass 456.586 g/mol
3D model (JSmol)

Pipendoxifene (INN) (developmental code name ERA-923) is a nonsteroidal selective estrogen receptor modulator (SERM) that was under development by Ligand Pharmaceuticals and Wyeth-Ayerst Laboratories (now Wyeth) for the treatment of breast cancer but was not marketed.[1][2][3] It is a member of the 2-phenylindole group of SERMs and is structurally related to zindoxifene and the marketed bazedoxifene.[2][3] The drug reached phase II clinical trials before its development was discontinued.[1][2] It was synthesized at the same time as bazedoxifene and was intended as a backup drug for bazedoxifene, only to be developed further if bazedoxifene had failed in clinical trials.[1][2] No further development was reported after 2002 and it was formally announced that development had been terminated in November 2005.[1][4]

Unlike the SERM raloxifene, pipendoxifene is devoid of uterotrophic activity in immature/ovariectomized rodents.[3][5]

References[edit]

  1. ^ a b c d http://adisinsight.springer.com/drugs/800011640
  2. ^ a b c d Gordon W. Gribble (9 October 2010). Heterocyclic Scaffolds II:: Reactions and Applications of Indoles. Springer Science & Business Media. pp. 14–. ISBN 978-3-642-15732-5. 
  3. ^ a b c Michelle Prudhomme (14 June 2013). Advances in Anticancer Agents in Medicinal Chemistry. Bentham Science Publishers. pp. 368–369. ISBN 978-1-60805-496-1. 
  4. ^ Eckhard Ottow; Hilmar Weinmann (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 95–. ISBN 978-3-527-62330-3. 
  5. ^ Antonio Cano; Joacquim Calaf i Alsina; Jose Luis Duenas-Diez (22 September 2006). Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs. Springer Science & Business Media. pp. 58–. ISBN 978-3-540-34742-2. 

External links[edit]